Ofloxacin: Nursing Drug Guide, Tendon Injury & Hold Rules
Healthcare medication guide: before every scheduled dose, screen for fluoroquinolone tendon injury (especially age over 60 and concurrent prednisone), peripheral neuropathy and CNS toxicity, myasthenia gravis history, twice-daily MAR accuracy, and separation from magnesium or aluminum antacids—ofloxacin can cause irreversible tendon rupture, nerve injury, and serious CNS effects.
Ofloxacin and other fluoroquinolones are associated with disabling and potentially irreversible serious adverse reactions that may occur together—including tendinitis and tendon rupture (most often the Achilles tendon), peripheral neuropathy, and central nervous system effects. Risk is highest in patients over 60, those taking corticosteroids, and patients with kidney, heart, or lung transplants. Labeling also warns of QT interval prolongation with uncorrected hypokalemia or QT-prolonging drugs. Avoid ofloxacin in myasthenia gravis. Before every dose, complete medication reconciliation, assess gait and joint complaints, review potassium and ECG risk, and hold plus escalate at the first sign of tendon pain, neuro symptoms, or serious hypersensitivity.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before the first and each subsequent dose, screen quinolone allergy, tendon and joint symptoms, corticosteroid and transplant risk factors, renal function for interval adjustment when CrCl is below 50 mL/min, and antacid or iron timing. Hold ofloxacin and notify the prescriber or pharmacist for new heel or shoulder pain, confusion or tremor, burning numbness in hands or feet, serious rash, or watery diarrhea with fever.
Most common brand names
Ofloxacin is available as generic tablets and, in some markets, as Floxin and other brand formulations. FDA tablet labeling includes 200 mg, 300 mg, and 400 mg strengths. The same active ingredient is also supplied as ophthalmic and otic solutions—verify route and formulation before administration; ear/eye drops are not interchangeable with oral tablets.
Ofloxacin is a racemic fluoroquinolone; levofloxacin is the active (S)-enantiomer and is usually dosed once daily. Do not confuse ofloxacin with ciprofloxacin or moxifloxacin on the MAR; document quinolone allergy when present.
Why we give it — Indications
Ofloxacin treats infections caused by susceptible organisms when benefit outweighs fluoroquinolone risks. Nurses commonly see it for urinary tract infection, complicated UTI, pneumonia, skin and soft-tissue infection, prostatitis, pelvic inflammatory disease, and gonorrhea regimens per prescribing information.
| Use (adults, oral examples) | Typical labeled dose (every 12 h) | Duration (usual) |
|---|---|---|
| Uncomplicated cystitis (E. coli or K. pneumoniae) | 200 mg every 12 hours | 3 days |
| Uncomplicated cystitis (other approved pathogens) | 200 mg every 12 hours | 7 days |
| Complicated UTI | 200 mg every 12 hours | 10 days |
| Community-acquired pneumonia | 400 mg every 12 hours | 10 days |
| Chronic bacterial prostatitis | 300 mg every 12 hours | 6 weeks |
On a small screen, swipe or scroll sideways to see the full table.
Labeling reserves ofloxacin for uncomplicated cystitis when patients have no alternative treatment options, because disabling serious adverse reactions can occur. FDA drug safety communications also advise restricting oral fluoroquinolones for some uncomplicated infections when other options are available. Follow institutional antimicrobial stewardship—nurses escalate concerns when fluoroquinolones are ordered without a clear susceptibility or safety rationale.
How it works
Ofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication in susceptible bacteria. Nursing focus extends beyond coverage: ofloxacin carries class warnings for tendon injury, peripheral neuropathy, CNS toxicity, and QT prolongation—these risks drive hold rules and patient teaching more than the mechanism alone. Quinolones may prolong the half-life of theophylline and enhance warfarin effect; monitor theophylline levels and INR when co-prescribed per labeling.
Dosing overview
Verify indication, renal function, and route against current prescribing information. Usual adult dosing is 200 mg to 400 mg orally every 12 hours depending on infection (DailyMed dosing chart). After a normal initial dose, adjust when creatinine clearance is below 50 mL/min per the impaired renal function subsection below. In cirrhosis with or without ascites, do not exceed 400 mg per day per labeling.
Renal dose adjustment (CrCl <50 mL/min, DailyMed)
| Creatinine clearance | Maintenance dose | Frequency |
|---|---|---|
| 20 to 50 mL/min | Usual recommended unit dose for the indication | Every 24 hours |
| <20 mL/min | Half the usual recommended unit dose | Every 24 hours |
| Hemodialysis or CAPD | Not specified in the reviewed prescribing information | |
On a small screen, swipe or scroll sideways to see the full table.
Pediatrics: Safety and efficacy in patients under 18 years have not been established; children have a higher chance of musculoskeletal adverse events per labeling.
Missed dose: Labeling states if a dose is missed, take it as soon as remembered; do not take two doses at the same time or more than two doses in one day.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Administration with food | May be given with or without food | Twice-daily MAR timing matters—pair doses with antacid separation rules |
| Half-life | ~4–5 h (major); ~9 h for steady-state accumulation (labeling) | Prolonged when renal function is reduced—apply renal adjustment table |
| Antacids / multivalent cations | Reduced absorption when given together | Give ofloxacin at least 2 hours before or 2 hours after magnesium/aluminum antacids, sucralfate, iron, zinc, or didanosine products per labeling |
| Elimination | Primarily renal | Trend basic metabolic panel / creatinine in chronic kidney disease or acute kidney injury |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Allergy history: ofloxacin, any fluoroquinolone, or product component
- MAR review for QT-prolonging drugs (e.g., Class IA/III antiarrhythmics), warfarin, corticosteroids, and antidiabetic agents (hypo-/hyperglycemia risk per labeling)
- Recent renal function and potassium; ECG/QT history when QT-prolonging co-therapy is present
- History of myasthenia gravis—avoid ofloxacin per labeling
- Gait and joint assessment (tendon risk); mental status baseline for CNS effects
- Scheduled antacids, iron, or sucralfate—plan 2-hour before / 2-hour after separation
Contraindications
- Known hypersensitivity to ofloxacin or other quinolone antibacterials
- Known history of myasthenia gravis (avoid per labeling)
Important interactions
| Drug / factor | Effect | Nursing action |
|---|---|---|
| Warfarin | May enhance anticoagulant effect | Monitor prothrombin time/INR closely during concurrent therapy |
| Class IA/III antiarrhythmics | Additive QT prolongation risk | Avoid combination when possible; correct hypokalemia; monitor ECG per prescriber |
| Magnesium/aluminum antacids, iron, calcium, zinc | Reduced ofloxacin absorption | Separate by at least 2 h before or 2 h after ofloxacin |
| NSAIDs | May increase CNS stimulation and seizures | Monitor for tremor, confusion, or seizures—especially with renal impairment |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral tablets: May be administered without regard to food per labeling. Maintain adequate hydration to prevent highly concentrated urine (crystalluria reported with quinolones). Use medication administration rights and swallow with water.
- Administer at least 2 hours before or 2 hours after antacids containing magnesium or aluminum, sucralfate, or products with calcium, iron, or zinc
- Independent double-check of warfarin and QT-prolonging combinations on the MAR
- Document administration, fluid intake, and any joint or neuro complaints
- IV ofloxacin: follow institutional IV antibiotic and infusion protocols when ordered
Expected therapeutic response
- Decreasing fever and improving dysuria, urgency, or perineal discomfort when treating susceptible genitourinary infection
- Improving respiratory symptoms and white blood cell trend when treating susceptible respiratory infection
- Stable mental status without new confusion, tremor, or insomnia
- No new tendon pain or gait change during or after therapy
- No new QT-related symptoms (syncope, palpitations) when ECG risk factors are present
Red flags — Stop and act
Hold ofloxacin and escalate immediately when serious toxicity is suspected.
- Sudden pain, swelling, or inability to use a joint—possible tendon rupture; rest joint and notify prescriber urgently
- Confusion, hallucinations, tremor, seizure, or suicidal thoughts—CNS toxicity per labeling
- Burning, tingling, or numbness in hands or feet—possible peripheral neuropathy; stop drug to prevent irreversible injury
- Syncope or palpitations with QT-prolonging co-therapy or hypokalemia—evaluate ECG per prescriber
- Signs of hepatitis: jaundice, dark urine, severe abdominal pain
- Angioedema, bronchospasm, or systemic allergic reaction (some after first dose)
- Serious rash or mucosal involvement
- Watery diarrhea, abdominal pain, fever—evaluate for C. difficile colitis
- Worsening weakness or respiratory distress in myasthenia gravis
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Nausea, headache, diarrhea, insomnia, dizziness | Common in trials (e.g., nausea 10%, headache 9% in one study group per labeling) | Supportive care; differentiate mild GI upset from CDAD or hepatitis |
| Tendinitis / tendon rupture | Boxed warning; higher risk age >60, steroids, transplant | Stop drug, rest affected limb, urgent prescriber/surgical review |
| CNS effects | Confusion, tremor, seizures; may follow first dose | Stop drug, neurologic assessment, fall precautions |
| Peripheral neuropathy | May be irreversible if continued | Stop at first sensory symptoms; document and notify prescriber |
| QT prolongation / torsade de pointes | Rare; avoid in known QT prolongation and uncorrected hypokalemia | Correct potassium; monitor ECG; hold QT-prolonging co-drugs per prescriber |
| Hepatotoxicity / serious hypersensitivity | Includes fatal cases postmarketing | Stop drug; order liver function tests per prescriber; treat severe reaction per protocol |
| CDAD | Reported with nearly all antibacterials | Isolation precautions per facility; stool studies per order |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Information on overdosage is limited in labeling. In acute overdosage, the stomach should be emptied, the patient observed, and appropriate hydration maintained.
Management
Postmarketing reports describe CNS effects (drowsiness, dizziness, disorientation, slurred speech) after large IV doses. Ofloxacin is not efficiently removed by hemodialysis or peritoneal dialysis per prescribing information. No specific antidote is listed in the reviewed prescribing information. Contact local poison control or toxicology services per facility protocol and local emergency guidance for severe overdose.
Look-alike / sound-alike and error prevention
- Ofloxacin vs levofloxacin—similar names; ofloxacin is usually twice daily, levofloxacin usually once daily
- Ofloxacin vs ciprofloxacin / moxifloxacin—different fluoroquinolones; confirm strength (200/300/400 mg) and interval
- Oral vs otic vs ophthalmic—same generic name, different routes; verify product on MAR
- Renal adjustment—errors are common when CrCl drops below 50 mL/min; pharmacy should verify q24h or half-dose rules
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Tendon screen | Ask about exercise, steroids, and new heel or shoulder pain at every shift |
| QT / potassium | Flag hypokalemia and amiodarone or sotalol on MAR before giving dose |
| Antacid timing | Chart separation from PPI/antacid/iron—many “given” doses are not absorbed |
| Hydration | Encourage fluids per plan—crystalluria risk with concentrated urine |
| Commonly missed | Continuing ofloxacin after tendon pain; giving with breakfast calcium supplement |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults (>60) | Highest tendon rupture risk; greater QT-interval sensitivity with QT-prolonging co-drugs |
| Corticosteroid therapy | Further increased tendon rupture risk—coordinate with prescriber before starting |
| Organ transplant recipients | Labeling identifies kidney, heart, or lung transplant as higher tendon risk |
| Renal impairment (CrCl <50) | After normal initial dose, use usual unit dose q24h (CrCl 20–50) or half unit dose q24h (CrCl <20) |
| Myasthenia gravis | Avoid ofloxacin—postmarketing deaths and ventilatory failure reported |
| Pregnancy | Use only if potential benefit justifies potential risk to the fetus per labeling |
| Lactation | Detected in human milk; serious infant reactions possible—discontinue nursing or drug per labeling decision |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Joint and tendon symptoms, gait, and ability to bear weight
- Mental status, sleep, tremor, or new neurologic complaints
- Renal function and creatinine clearance trend for renal interval adjustment
- Serum potassium and ECG/QT when QT-prolonging drugs are concurrent
- INR or prothrombin time when warfarin is concurrent
- Blood glucose when antidiabetic agents are concurrent (dysglycemia reported)
- GI tolerance, hydration, and stool character
- Infection response: temperature, WBC, urine symptoms, or respiratory status per plan
Document
- Tendon, QT, and interaction screening before first dose
- Antacid or multivalent cation separation education and administration times
- Any held doses with prescriber/pharmacist notification and patient symptoms
- Patient teaching on tendon pain, neuro symptoms, photosensitivity, and severe diarrhea
Patient teaching
- Take exactly as directed every 12 hours (or per pharmacy renal adjustment) at about the same times each day; schedule iron, calcium, or stomach medicines at least 2 hours before or after doses
- Stop exercising at the first sign of tendon pain, swelling, or inability to move a joint, and contact the prescriber immediately
- Report confusion, tremor, depression, insomnia, numbness, tingling, or burning in hands or feet promptly
- Report watery diarrhea, blood in stool, or severe abdominal pain—even after stopping the antibiotic
- Avoid excessive sunlight or UV exposure—photosensitivity/phototoxicity reported with fluoroquinolones
- Do not share antibiotics; complete the course only if the prescriber continues the drug after safety review
- Breastfeeding: discuss risks and benefits with the prescriber—drug is present in breast milk per labeling
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known hypersensitivity to ofloxacin or any fluoroquinolone
- Known history of myasthenia gravis
- New or worsening tendon pain, swelling, inflammation, or joint weakness
- Confusion, hallucinations, tremor, seizure, or other significant CNS toxicity
- Peripheral neuropathy symptoms (pain, burning, tingling, numbness, weakness)
- Serious allergic reaction, severe rash, or signs of hepatitis
- Watery diarrhea with fever or suspected C. difficile pending evaluation
- Uncorrected hypokalemia or new syncope/palpitations with QT-prolonging co-therapy until prescriber review
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Ofloxacin requires twice-daily oral dosing for many regimens—but fluoroquinolone boxed warnings mean nurses must pair each dose with tendon and neuro surveillance, not only infection response.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and renal interval adjustment verified when CrCl <50 mL/min
- Quinolone allergy and myasthenia gravis contraindication reviewed on MAR
- Warfarin, QT-prolonging drugs, corticosteroids, and antidiabetic agents flagged
- Antacid, iron, calcium, or zinc products scheduled outside the 2-hour before / 2-hour after window
2. Safety badge
Fluoroquinolone — tendon, CNS, neuropathy, and QT screening requiredTreat tendon and QT risk with the same rigor as institutional high-alert workflows even when the product is not on a formal high-alert list in every facility.
3. Hold and question rules
- Any new heel or shoulder pain → hold next dose and notify prescriber same shift
- Potassium 3.2 mEq/L with amiodarone on MAR → hold until electrolyte and ECG plan clarified
- Patient on prednisone with new gait change → urgent prescriber review before further doses
4. Critical teach-back questions
- “What joint symptoms should you report immediately?” (Patient should name pain, swelling, or inability to use a joint and stopping exercise.)
- “How should you take antacids or iron with this antibiotic?” (Patient should describe separating doses by at least 2 hours before or after.)
5. Care coordination
Pharmacist: Renal interval adjustment, warfarin/INR and theophylline monitoring, QT and potassium review, antacid timing
Prescriber: Alternative antibiotic when fluoroquinolone risk outweighs benefit; tendon or neuropathy management
🧠 Quick mental checklist
- Is the patient over 60, on steroids, or post-transplant?
- Are warfarin, amiodarone/sotalol, or other QT-prolonging drugs on the MAR?
- What is creatinine clearance—is q24h or half-dose renal adjustment reflected on the MAR?
- Is potassium normal and were antacids or iron separated by 2 hours?
- Any new tendon pain, confusion, tremor, numbness, syncope, or watery diarrhea?
Ofloxacin NCLEX practice questions
Practice NCLEX-style clinical judgment practice for ofloxacin tendon injury and dosing safety using a tabbed case panel (MAR, labs, I&O, nursing notes), then priority action, cue recognition (SATA), trend interpretation, documentation cloze, ordered response, and matrix urgency—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, I&O, and nursing note details for this case.
- Ofloxacin 300 mg PO every 12 h (day 4 of chronic bacterial prostatitis regimen)
- Prednisone 20 mg PO daily — given 0800
- Ferrous sulfate 325 mg PO with dinner — scheduled 1730
- Ofloxacin 300 mg due 2100
- Creatinine 1.6 mg/dL (baseline 1.2); estimated CrCl ~36 mL/min per pharmacy
- Potassium 3.9 mEq/L
- Urinalysis: improving pyuria per team; culture pending
- INR 2.4 on warfarin 4 mg daily
- Oral intake ~1.4 L today; encouraged fluids per plan
- Urine output adequate; dysuria improving
- No fever since yesterday (afebrile 24 h)
- 61-year-old reports burning pain at right Achilles tendon when walking; refuses to bear full weight
- Started ofloxacin 48 h ago after outpatient urology visit
- Iron tablet taken with dinner 35 minutes before scheduled 2100 ofloxacin
- Pharmacy note: “CrCl 36—after normal initial dose, usual unit dose should be q24h, not q12h”
Answer key & rationale
Frequently asked questions
Why are tendon injury and peripheral neuropathy the main nursing safety concerns with ofloxacin?
Prescribing information carries a boxed warning for disabling and potentially irreversible serious reactions including tendinitis and tendon rupture, peripheral neuropathy, and central nervous system effects that may occur together. Risk is highest over age 60, with corticosteroids, or after organ transplant. Stop at the first sign of tendon or neuro symptoms.
When should a nurse hold ofloxacin?
Hold for hypersensitivity to ofloxacin or any quinolone; avoid in myasthenia gravis; stop for new tendon pain, swelling, or inability to use a joint; CNS toxicity such as confusion, tremor, or seizures; peripheral neuropathy symptoms; serious rash or hepatitis; watery diarrhea with fever suggesting C. difficile; or when QT-prolonging co-therapy and hypokalemia are not corrected until prescriber or pharmacist review.
How is ofloxacin dosed when creatinine clearance is below 50 mL/min?
For creatinine clearance above 50 mL/min, use the usual 200 to 400 mg every 12 hours per indication. When creatinine clearance is below 50 mL/min, give a normal initial dose then adjust: CrCl 20 to 50 mL/min uses the usual unit dose every 24 hours; CrCl below 20 mL/min uses half the usual unit dose every 24 hours per prescribing information.
What adverse effects matter most for nurses?
Priority nursing concerns include tendinitis and tendon rupture, peripheral neuropathy, CNS effects, QT prolongation, serious hypersensitivity and hepatotoxicity, C. difficile-associated diarrhea, myasthenia gravis exacerbation, and common reactions such as nausea, headache, diarrhea, insomnia, constipation, and dizziness.
Is ofloxacin safe in pregnancy and breastfeeding?
Safety and efficacy in pregnancy have not been established; ofloxacin is pregnancy category C and should be used only if benefit justifies risk to the fetus. After a single 200 mg dose, milk concentrations were similar to plasma; because of potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug.
References
- U.S. National Library of Medicine. Ofloxacin tablet — Full prescribing information. DailyMed (setid c677b35c-0432-4ee5-af57-1f95449c48b6).https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c677b35c-0432-4ee5-af57-1f95449c48b6
- U.S. Food and Drug Administration. FDA advises restricting use of oral fluoroquinolone antibiotics for certain uncomplicated infections. Drug Safety Communication.https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-advises-restricting-use-oral-fluoroquinolone-antibiotics-certain
- Drugs and Lactation Database (LactMed). Ofloxacin. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501055/
- U.S. National Library of Medicine. Ofloxacin — MedlinePlus drug information.https://medlineplus.gov/druginfo/meds/a691005.html
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.